A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
← catalyst calendarNCT07101328 · readout ≤ 254 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
215estimated
Sites
50
Countries
Australia, Canada, Denmark +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-28 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lymphoma, Non-Hodgkin
- B-cell Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
- Lymphoma, B-cell Marginal Zone
- Waldenstrom Macroglobulinemia
- Lymphoma, Mantle Cell
Intervention
- Drug: LY4152199 - IV
Primary outcome
what the primary-completion date above is the date OFPhase 1 - Number of Participants with Dose Limiting Toxicities (DLT) of LY4152199
measured Cycle 1 Day 1 through Cycle 2 Day 8 (35 days)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed